Aktis Oncology (NASDAQ:AKTS) executives outlined the company’s strategy to expand the use of targeted radiopharmaceuticals beyond the limited set of currently approved products, emphasizing a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results